A phase I dose escalation study of eryaspase in combination with modified FOLFIRINOX in locally advanced and metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Yin, Chao
Marshall, John
Macke, Laura Ann
He, Aiwu Ruth
Bouker, Kerrie
Weinberg, Benjamin Adam
Mukherji, Reetu
Weiner, Louis M.
Wang, Hongkun
Geng, Xue
Hoke, Frank
Youssoufian, Hagop
El-Hariry, Iman
Noel, Marcus Smith
机构：
[1] Virginia Canc Specialists, Fairfax, VA USA
[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ctr Cure Gastrointestinal Canc, Washington, DC USA
[3] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
[4] Georgetown Univ, Lombardi Comprehens Canc Ctr, Div Hematol & Oncol, Washington, DC USA
[5] Georgetown Univ, Med Ctr, Washington, DC USA
[6] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[7] Georgetown Univ, Dept Biostat Bioinformat & Biomathemat, Washington, DC USA
[8] Erytech Pharma Inc, Cambridge, MA USA
[9] Brown Univ, Providence, RI USA
[10] Erytech Pharma Inc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16288
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Circulating microRNAs as dynamic biomarkers of response to treatment with FOLFIRINOX combination therapy in advanced pancreatic ductal adenocarcinoma
    Meijer, Laura L.
    Frampton, Adam E.
    Garajova, Ingrid
    Caparello, Chiara
    Le Large, Tessa Y. S.
    Funel, Niccola
    Vasile, Enrico
    Stebbing, Justin
    Krell, Jonathan
    Kazemier, Geert
    Giovannetti, Elisa
    LANCET, 2017, 389 : 68 - 68
  • [42] A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
    Duffy, A.
    Kortmansky, J.
    Schwartz, G. K.
    Capanu, M.
    Puleio, S.
    Minsky, B.
    Saltz, L.
    Kelsen, D. P.
    O'Reilly, E. M.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 86 - 91
  • [43] Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
    Alhanafy, A. M.
    Abd El Bary, N.
    Hegazy, O.
    Abd El Ghany, A.
    Soliman, S. H.
    Ahmed, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S902 - S902
  • [44] Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer
    Nishida, Tsutomu
    Tsutsui, Shusaku
    Yamamoto, Katsumi
    Konishi, Koji
    Hayashi, Yoshito
    Iijima, Hideki
    Tsujii, Masahiko
    Takeda, Yutaka
    Kitagawa, Toru
    Yoshioka, Yasuo
    Inoue, Takehiro
    Hayashi, Norio
    PANCREATOLOGY, 2010, 10 (01) : 60 - 65
  • [45] FOLFIRINOX FOR LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA. RESULTS OF AN AGEO MULTICENTRIC PROSPECTIVE STUDY
    Marthey, L.
    Sa-Cunha, A.
    Blanc, J. F.
    Cueff, A.
    Francois, E.
    Trouilloud, I.
    Malka, D.
    Bachet, J.
    Coriat, R.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 238 - 238
  • [46] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [47] Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study
    Ioannou, S.
    Papaxoinis, G.
    Korkolis, D.
    Kypreos, D.
    Gouveris, P.
    Zouki, D.
    Kardara, V.
    Exarchos, K.
    Karianakis, G.
    Bitsas, I.
    Adamou, V.
    Koronakis, G.
    Stavrou, N.
    Demiri, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S301 - S301
  • [48] A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
    Jo, Jung Hyun
    Jung, Dawoon E.
    Lee, Hee Seung
    Park, Soo Been
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Cho, Sangsook
    Song, Si Young
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (09) : 1565 - 1577
  • [49] De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line.
    Dennen, Syvart
    Shao, Anran
    Dennen, Syvart
    Cockrum, Paul
    Paluri, Ravi Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 628 - 628
  • [50] A phase II study of neoadjuvant FOLFIRINOX and chemoradiation in locally advanced pancreatic cancer
    D'Ercole, Gabriele
    Fiore, Michele
    Petrianni, Gian Marco
    Trecca, Pasquale
    Benincasa, Martina
    Floreno, Barnaba
    Ippolito, Edy
    Caputo, Damiano
    Tonini, Giuseppe
    Coppola, Roberto
    Ramella, Sara
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2274 - S2275
12345